Skip to main content

Featured

Washington Signals Swift Timeline for Iran Operation

US official said that achievable objectives of Operation Epic Fury are expected to last about six weeks. The White House says it expects U.S. military objectives in Iran to be achieved within four to six weeks , emphasizing that Operation Epic Fury is progressing as planned. According to Press Secretary Karoline Leavitt, the campaign has already weakened Iran’s naval capabilities and sharply reduced missile attacks, putting the U.S. “well on its way” toward its strategic goals.  The operation, now in its second week, focuses on dismantling Iran’s ballistic missile infrastructure, degrading its navy, and limiting its pathway to nuclear weapons. Officials maintain that U.S. stockpiles and resources are sufficient to sustain the mission through its projected timeline.  As regional tensions escalate, Washington continues to frame the operation as both achievable and time‑bound, reinforcing its confidence in meeting objectives by early April.
Post a Comment
Read more

article

Labels

Alzheimer’s vaccines get a boost from new drug approval

 

After decades of disappointment and controversy, the field of Alzheimer’s disease research has finally seen a breakthrough with the approval of the first drug that targets the underlying pathology of the condition. 

Aducanumab, a monoclonal antibody that clears amyloid plaques from the brain, was granted accelerated approval by the US Food and Drug Administration in June 2021, despite mixed results from clinical trials and objections from some experts. 

The drug’s approval has rekindled interest in other therapeutic approaches that aim to prevent or slow down the progression of Alzheimer’s, such as vaccines that stimulate the immune system to attack amyloid or tau, another protein that accumulates in the brains of people with the disease. 

Several vaccine candidates are currently in various stages of development and testing, and some researchers are optimistic that they could offer a more effective and convenient way to treat Alzheimer’s than infusions of antibodies.


Labels:

Comments

Post a Comment